Immunome has acquired 3 companies, including 3 in the last 5 years.
Immunome’s largest acquisition to date was in 2023, when it acquired Atreca - Antibody s Related Assets and Materials for $6M. Immunome has acquired in 3 different US states. The Company’s most targeted sectors include life science (100%).
18702 North Creek Parkway Suite 100,
Bothell, Washington
98011
United States,
(425) 939-7410
www.immunome.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2024-02-06 |
Ayala Pharmaceuticals - AL102 · Life Science
Rehovot, Pennsylvania Ayala Pharmaceuticals' AL102 is an investigational small molecule gamma-secretase inhibitor currently being evaluated in the randomized Phase 3 RINGSIDE international trial for the treatment of desmoid tumors – a debilitating soft tissue malignancy. Ayala Pharmaceuticals' AL102 is based in Rehovot, Pennsylvania. |
- | Divestiture |
Ayala
|
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
